Specialty Pharmacy

Austedo is the second product approved for Huntington’s Disease.

Medical pharmacy trend report shows significant impact from specialty drugs.

German shepherds undergo training to detect breast cancer through smell.

Combination treatment produces a complete response in mice with epithelial cancer.

Grant E. Knowles, PharmD, discusses how the projected growth in specialty drug spending may change the patient experience in the years ahead.

Toxin produced by cigarette smoke accelerates the growth of tumors.

Top news of the day from across the health care landscape.

Cytomegalovirus disease coinfection without symptoms is common in people with HIV.

Current platforms are not designed for the dynamic needs of today’s specialty pharmacy providers.

More than 96% of Prime Therapeutics members taking Harvoni cured of hepatitis C virus.

Tyrosine kinase inhibitor improves survival in patients with rare lung cancer.

Ambitious project marks new era for pancreatic cancer patients, investigators say.

Top news of the day from across the health care landscape.

Sirukumab is a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity in RA.

Defendants charged with conspiracy to commit health care fraud and money laundering.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how to optimize a drug adherence program in specialty pharmacy.

Top news of the week in oncology and cancer drug development.

Health care reform discussed at Premier Inc’s 6th Annual Specialty Pharmacy Executive Retreat.

Overexpression of protein reveals why breast cancer spreads quickly.

Genetic testing and imaging tests will improve neuroendocrine treatment.

Top five most popular articles this week on Specialty Pharmacy Times.

Scientists identify specific genes that cooperate with a well-known tumor suppressor gene.

The smartphone hit the shelves recently.

Study identifies 2 immune system molecules that may play a key role in drug-resistance.

The rheumatoid arthritis (RA) drug market is projected to reach approximately $28.5 billion by 2025.

More biosimilar approvals may lead to lower costs.

Study identifies potential Achilles heel of kinase-driven cancers.

Majority of patients were free from local recurrence after 1 year of reirradiation with an advanced form of proton therapy.